MedGenome, a US-based global precision medicine company specialising in omics solutions, announced on Tuesday that it has named Martin Dewhurst as the chairman of its Advisory Board.

In the new role, Dewhurst will collaborate with the company's Research services team in the US to build strong connections with the global life sciences community.

Dewhurst is a healthcare investor, advisor and board member with a focus on fostering growth and innovation. He has played crucial roles across growth VC investing with Lightrock, M&A advisory at PJT, and board/advisor positions for companies such as Distalmotion and now MedGenome. He has headed McKinsey's global life sciences practice for seven years, co-founded and led the McKinsey Health Institute. He has served across geographies in Europe, the US, Asia, the Middle East, and South Africa.

Dr Felix Olale, chairman of MedGenome's board of directors, and global co-lead for Healthcare Investments at LeapFrog Investments, said: "MedGenome is dedicated to advancing global healthcare by expanding genomic datasets and fostering more inclusive and collaborative research and drug discovery practices. We are thrilled to welcome Martin Dewhurst as the chair of our Advisory Board at MedGenome. His strategic vision and wealth of experience will undoubtedly strengthen our position as a leader in the global omics space."